Neurology
Articles filed under Neurology.
EMEA positive opinion for prasugrel (Efient)
Press release about the positive opinion of the CHMP for the antiplatelet agent Efient (prasugrel): COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE SUMMARY OF POSITIVE OPINION for EFIENT International Nonproprietary Name (INN): prasugrel On 18 December 2008 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending to grant a marketing
EMEA press release: CHMP adopted a positive opinion about japanese encephalitis vaccine (Ixiaro)
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE SUMMARY OF POSITIVE OPINION for IXIARO Common Name: Japanese Encephalitis vaccine, inactivated, adsorbed On 18 December 2008 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending to grant a marketing authorisation for the medicinal product IXIARO, containing a target total protein amount of
Antiepileptic drugs (AEDs): FDA requires warnings about suicidal thoughts and behaviors (suicidality)
The FDA will require manufacturers of antiepileptic drugs (AEDs) to inclued a warning about the increased risk of suicidal thoughts and behaviours when using these drugs. This is a transcript of the original press release dated Dec. 16, 2008: FDA Requires Warnings about Risk of Suicidal Thoughts and Behavior for Antiepileptic Medications The U.S. Food
FDA: statins do not increase the risk of amyotrophic lateral sclerosis (ALS)
From FDA’s patient safety news website: Statin Use and the Risk of ALS A recent FDA analysis provides new evidence that using statins does not increase the risk of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease also known “Lou Gehrig’s Disease.” Cholesterol-lowering statins such as Lipitor (atorvastatin calcium) and Zocor (simvastatin) have been shown to
FDA video on Ephedrine and Epinephrine: how to prevent mistakes in their administration.
From FDA Patient Safety News: “Drug Name Confusion: Ephedrine and Epinephrine The Institute for Safe Medication Practices (ISMP) is warning again about the possibility of mix-ups between ephedrine and epinephrine. Not only do the names of these drugs look and sound similar, but since they’re both used as vasopressors and vasoconstrictors, they’re often stored next
Alpha 1 adrenergic receptors antagonists (blockers): mechanism of action animation
Additional information about alpha 1 blocking drugs. Source: Bertram G. Katzung, Basic & Clinical Pharmacology (Mc Graw-Hill Medical, 2007) ” Phentolamine, an imidazoline derivative, is a potent competitive antagonist at both alpha 1 and alpha 2 receptors . Phentolamine causes a reduction in peripheral resistance through blockade of alpha 1 receptors and possibly alpha 2
Epinephrine (adrenaline) mechanism of action: animation showing the signal transduction process
Drugs related to this animation Adrenoceptor-Activating & Other Sympathomimetic Drugs:Dobutamine, Ephedrine, Epinephrine, Hydroxyamphetamine, Isoproterenol, Methylphenidate, Naphazoline, Norepinephrine. Source of animation: Lodish, et al., Molecular Cell Biology, Fifth Edition, W. H. Freeman & Co.Developed by Sumanas, Inc.
Zolpidem, zoplicone and zaleplon (z-drugs) side effects profile: Australian Prescriber press release
Hypnotic hazards and effects of z-drugs immeasurable “It is difficult to know the extent of use and adverse effects of zolpidem and other z-drugs (zopiclone and zaleplon) because they have never been listed on the Australian Pharmaceutical Benefits Scheme, senior Sleep Disorders Physician Dr Les Olson writes in the latest edition of Australian Prescriber.
Nitrous oxide: neurological and haematological toxic effects. Update by the MHRA
Nitrous oxide: neurological and haematological toxic effects, especially with prolonged use Keywords: Nitrous oxide, neurological, haematological toxicity “Neurological and haematological toxic effects can occur with prolonged use of nitrous oxide. Neurological effects can occur without preceding overt haematological changes.Assessment of vitamin B12 levels should be considered before nitrous oxide anaesthesia in people with risk factors
Theraloc (nimotuzumab) for high grade glioma: the manufacturer withdrawed its marketing application
EMEA press release about the marketing authorization withdrawal for the monoclonal antibody nimotuzumab (Theraloc): Oncoscience AG withdraws its application for Theraloc (nimotuzumab) The European Medicines Agency (EMEA) has been formally notified by Oncoscience AG of its decision to withdraw its application for a centralised marketing authorisation for the medicine Theraloc (nimotuzumab), 5 mg/ml concentrate for solution for
Drugs acting on the autonomic nervous system: animation showing their mechanism of action
The following is a list of drugs related to the animation: Adrenoceptor-Activating & Other Sympathomimetic Drugs Dobutamine, Ephedrine, Epinephrine, Hydroxyamphetamine, Isoproterenol, Methylphenidate, Naphazoline, Norepinephrine. Adrenoceptor Antagonist Drugs Acebutolol, Atenolol, Betaxolol, Bisoprolol, Carteolol, Carvedilo,l Carvedilol, Esmolol, Labetalol, Metoprolol, Nadolol, Pindolol, Propranolol, Sotalol, Timolol. Cholinoceptor-Activating (Acetylcholine receptor stimulants) Acetylcholine, Bethanechol, Carbachol, Cevimeline, Pilocarpine. Cholinoceptor-Blocking Drugs (Cholinoceptor antagonists)
Toviaz (fesoterodine fumarate): new drug to treat overactive bladder
FDA press release about the approval of Toviaz (fesoterodine fumarate): The U.S. Food and Drug Administration has approved a new drug to help patients suffering from overactive bladder (OAB). Toviaz (fesoterodine fumarate) works by relaxing the smooth muscle tissue of the bladder, thus reducing the urinary frequency, urge to urinate, and sudden urinary incontinence (leakage
Phenytoin and fosphenytoin linked to Stevens Johnson syndrome and toxic epidermal necrolysis
From the FDA website: FDA is investigating new preliminary data regarding a potential increased risk of serious skin reactions including Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) from phenytoin therapy in Asian patients positive for a particular human leukocyte antigen (HLA) allele, HLA-B*1502. This allele occurs almost exclusively in patients with ancestry across